Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.

Cancer Causes Control · 2016 · PMC4703623 · PMID 26458884

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Combined this led to a marginally significant 8 % increase [OR of 1.08 (95% CI 1.00–1.15)] in the fraction of primary smears both classified as BMD and resulting in the detection of a CIN II lesion.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.